Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations
The infective SARS-CoV-2 is more prone to immune escape. Presently, the significant
variants of SARS-CoV-2 are emerging in due course of time with substantial mutations …
variants of SARS-CoV-2 are emerging in due course of time with substantial mutations …
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
An early warning system for emerging SARS-CoV-2 variants
An early warning system for emerging SARS-CoV-2 variants | Nature Medicine Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …
content Thank you for visiting nature.com. You are using a browser version with limited support …
Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
AS Gonzalez-Reiche, H Alshammary… - Nature …, 2023 - nature.com
Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have
been reported in immune-compromised individuals and people undergoing immune …
been reported in immune-compromised individuals and people undergoing immune …
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
JM Carreño, G Singh, J Tcheou, K Srivastava… - Vaccine, 2022 - Elsevier
Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent
coronavirus disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids …
coronavirus disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids …
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
The IMPACC cohort, composed of> 1,000 hospitalized COVID-19 participants, contains five
illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1 …
illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1 …
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023
Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following …
coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following …
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
B Mühlemann, SH Wilks, L Baracco, M Bekliz… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires
ongoing monitoring to judge the ability of newly arising variants to escape the immune …
ongoing monitoring to judge the ability of newly arising variants to escape the immune …
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm …
Background Several COVID-19 vaccines have been approved. The mRNA vaccine from
Pfizer/BioNTech (Comirnaty, BNT162b2; BNT) and the vector vaccine from AstraZeneca …
Pfizer/BioNTech (Comirnaty, BNT162b2; BNT) and the vector vaccine from AstraZeneca …